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Abstract
Introduction: Kawasaki disease (KD), an acute febrile disease, characterized by systemic vasculitis, predominantly
affects infants and children under 5 years of age. Coronary artery lesions (CALs) are its most critical complication,
and the etiology remains unknown yet. In order to explore the value of resistin, S100A12 and soluble receptor for
advanced glycation end products (sRAGE) in the pathophysiology of KD, we studied the serum levels of resistin,
S100A12 and sRAGE in different stages of KD.
Methods: Serum levels of resistin, S100A12 and sRAGE were measured by enzyme-linked immunosorbent assay
(ELISA) method in 15 healthy children and 40 KD patients at acute, afebrile and subacute stage.
Results: The resistin and S100A12 levels, including the ratio of resistin to sRAGE and S100A12 to sRAGE increased
significantly in the acute stage, and decreased progressively in the afebrile and subacute stage. However, the
sRAGE levels decreased significantly in the acute stage, and increased progressively in the afebrile and subacute
stage. In the acute, afebrile and subacute stage, the resistin levels were higher in intravenous immunoglobulin
(IVIG) non-responders (0.64 ± 0.30, 0.48 ± 0.35, 0.28 ± 0.19, × 102 ng/ml) than in IVIG responders (0.35 ± 0.24,
0.21 ± 0.19, 0.12 ± 0.05, × 102 ng/ml). In the acute and subacute stage, the S100A12 levels were higher in IVIG
non-responders (7.92 ± 2.61, 4.98 ± 4.75, × 102 ng/ml) than in IVIG responders (5.05 ± 3.22, 2.35 ± 2.26, × 102 ng/ml).
In the afebrile and subacute stage, the sRAGE levels were lower in IVIG non-responders (3.51 ± 2.64, 3.65 ± 3.27,
× 102 pg/ml) than in IVIG responders (6.00 ± 2.78, 7.19 ± 2.88, × 102 pg/ml). The resistin levels were positively correlated
with S100A12 levels. The sRAGE levels were negatively related with S100A12 and resistin levels.
Conclusions: Resistin, S100A12 and sRAGE are involved in the pathophysiology of KD.
Introduction
Kawasaki disease (KD), an acute febrile disease charac-
terized by systemic vasculitis, predominantly affects
infants and children under 5 years of age [1]. Coronary
artery lesions (CALs) are its most critical complication
[2], and as yet the etiology remains unknown.
Human resistin is a 12.5 kDa cysteine-rich peptide of
bioactive molecules produced by the adipose tissue, mono-
cytes and macrophages [3,4]. Although considered an adi-
pokine, importantly, resistin is expressed in macrophages
and plays important roles in systemic inflammation; it also
appears to be a predominant pro-inflammatory protein
associated with both acute and chronic inflammation
[5-9]. Resistin may have a potential role in the develop-
ment of endothelial dysfunction [10], thrombosis, angio-
genesis, inflammation and smooth muscle cell dysfunction
in cardiovascular disease (CVD) and atherosclerosis
[11-13]. There is increasing evidence from human clinical
and experimental studies that resistin has a pathogenic
role in the development and progression of atherosclero-
sis, coronary artery disease (CAD), and even heart failure
[14]. Resistin may have a pivotal role in the pathophysiol-
ogy of cardiovascular events.
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S100A12 is a member of the S100 family of calcium-
binding proteins. It is a key ligand of the receptor for
advanced glycation end products (RAGE), which is cur-
rently secreted by neutrophils, with low expression on
lymphocytes and monocytes [15]. S100A12 is also called
EN-RAGE (extracellular newly identified RAGE-binding
protein), proposed to stress its role as a receptor-mediated
signaling pathway. S100A12 binding with RAGE can acti-
vate the NF-B pathway to produce endothelial damage
and promote KD [16]. S100A12 is over-expressed at local
inflammatory sites, and its serum concentrations are asso-
ciated with individual disease activity [17].
It has been identified that soluble RAGE (sRAGE) corre-
sponds to the extracellular domain of circulating RAGE in
humans [18]. sRAGE has the same ligand-binding specifi-
city as RAGE and may serve as a competitor by binding
pro-inflammatory ligands, and consequently, preventing
them from reaching membrane RAGE even preventing
the development of inflammatory disease.
Nevertheless, the significance of these critical inflamma-
tion proteins to the risk of CALs or intravenous immuno-
globulin (IVIG)-resistance in KD remains largely unknown.
We found that S100A12 and RAGE expression on circulat-
ing endothelial cell surfaces increased significantly in KD
[19]. In order to explore the value of resistin, S100A12 and
protector sRAGE in the pathophysiology of KD, we studied
the serum levels of resistin, S100A12 and sRAGE in differ-
ent stages of KD.
Materials and methods
The study was approved by the ethical committee of the
Children’s Hospital, Zhejiang University School of Medi-
cine, China and was based on the institution’s guidelines
for human studies. The investigation conformed to the
principles outlined in the Declaration of Helsinki.
Informed consent was obtained from the patients’ parents.
Subjects
Forty patients with KD treated at the Children’s Hospital,
Zhejiang University School of Medicine were included in
this study. All patients fulfilled the diagnostic criteria [20]
and were treated with IVIG at 1 g/kg/d for 2 days and oral
aspirin at 30 to 50 mg/kg/d. After 3 to 5 days of treatment
when the patient’s temperature returned to normal, the
dose of aspirin was reduced to 3 to 5 mg/kg/d for
12 weeks. There were four IVIG-resistant KD patients,
whose temperature was still higher than 38°C after
48 hours of standard treatment, so they were continued
on IVIG at 1 g/kg/d for another 2 days. Nine patients,
including five girls and four boys, had CALs (defined as
coronary artery z-score > 5) [21] identified by echocardio-
graphy during the disease process. Six patients had CALs
in both the left and right coronary arteries, two in the left
coronary artery, and one in the right coronary artery. The
CALs in the majority of KD patients were temporary and
disappeared within 3 months, while in two patients they
persisted more than 3 months. Dipyridamole and warfarin
were given to patients with CALs depending on the sever-
ity of the lesions.
The disease process between 4 to 9 days, 10 to 13 days
and 14 to 21 days was defined as acute stage (at the time
of diagnosis on admission, prior to the initiation of IVIG
treatment), afebrile stage (after IVIG application and the
patients’ temperature had returned to normal for more
than 3 days), and subacute stage (patients had been dis-
charged from hospital). Fifteen healthy children attending
for a routine health examination were enrolled into the
control group.
Laboratory analysis
Blood samples were respectively collected in acute, afebrile
and subacute stages of patients and in healthy children.
Two milliliters of blood was collected from the ulnar vein.
The samples were centrifuged to yield serum immediately,
and were then kept at -20°C until analysis. White blood
cell (WBC) counts, platelet counts, serum C-reactive pro-
tein (CRP) and erythrocyte sedimentation rate (ESR) were
measured by conventional methods in our hospital labora-
tory. Serum levels of resistin, S100A12, and sRAGE were
measured by ELISA according to the manufacturer’s
instructions. Briefly, antibody-antigen reactions were used
to capture special proteins. Measurements were performed
in duplicate and the results were averaged.
We used the following reagents: human resistin immu-
noassay (catalog number DRSN00, Quantikine, R&D Sys-
tems, Minneapolis, MN, USA); S100A12/EN-RAGE ELISA
Kit (catalog number CY-8058, CircuLex™, Nagano, Japan);
ELISA kit for measuring sRAGE (catalog number DRG00,
Quantikine, R&D Systems, Minneapolis, MN, USA).
Statistical analysis
SPSS 16.0 software package was used for all statistical ana-
lyses. Except where indicated otherwise, the results were
expressed as mean (SD). Normal data analysis was per-
formed with analysis of variance (ANOVA) followed by
least significant difference (LSD) test for multiple compari-
sons; nonparametric data were analyzed by the Mann-
Whitney test. Correlations were analyzed using the partial
correlation test with age and gender as control variables.
Differences in parameters were considered significant
when the P-values were ≤ 0.05.
Results
Characteristics of the KD patients and healthy children
The clinical characteristics of 40 KD patients and 15
healthy children are summarized in Table 1. Resistin, the
product of resistin and S100A12, the ratio of resistin to
sRAGE, and the ratio of S100A12 to sRAGE increased
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significantly in the acute stage of KD, and decreased with
the course of the disease; there were no significant differ-
ences between patients with KD in the afebrile and suba-
cute stages compared with the control group. S100A12
increased significantly in the acute and afebrile stage of
KD, reaching the peak in the acute stage before IVIG
treatment, and decreased with the course of the disease;
there were no significant differences between patients in
the subacute stage of KD compared with the control
group. sRAGE levels decreased significantly in the acute,
afebrile and subacute stage of KD. Although the sRAGE
levels increased progressively with the course of the dis-
ease, the sRAGE level in the subacute stage remained
lower than in the control group.
Serum levels of resistin, S100A12, sRAGE in IVIG
responder and non-responder KD patients
Serum levels of resistin, S100A12, and sRAGE in IVIG
responder and non-responder KD patients are shown in
Table 2 and Figure 1. Not all KD patients were sensitive to
the treatment of IVIG. There were four IVIG-resistant KD
patients (one boy and three girls). In the acute, afebrile and
subacute stages of KD, although the resistin levels
decreased progressively with the course of disease, they
were higher in IVIG non-responders than in IVIG respon-
ders. The S100A12 levels also decreased progressively with
the course of disease, but in the acute and subacute stages
of KD, the S100A12 levels were higher in IVIG non-
responders than in IVIG responders. In the afebrile stage,
there was no difference between IVIG responders and
non-responders. The sRAGE levels increased progressively
with the course of disease, but increased slowly in IVIG
non-responders. In the afebrile and subacute stages of KD,
sRAGE levels were lower in IVIG non-responders than in
IVIG responders.
Serum levels of resistin, S100A12, sRAGE in KD patients
with and without CALs
Serum levels of resistin, S100A12 and sRAGE in KD
patients with and without CALs are shown in Table 3 and
Figure 2. Nine KD patients (four boys and five girls) devel-
oped CALs. In all KD patients, resistin and S100A12 levels
decreased progressively, and sRAGE levels increased pro-
gressively with the course of disease. Resistin, S100A12
and sRAGE levels did not differ significantly between KD
patients with CALs and without CALs.
Correlation between different parameters in patients
with KD
Table 4 shows the partial correlation coefficients of differ-
ent parameters in patients with KD. Correlation was
adjusted for gender and age. Significant correlations were
found between resistin, S100A12, sRAGE and established
inflammatory agents. Resistin levels were positively corre-
lated with S100A12 levels. The sRAGE levels were not
only negatively related with S100A12 levels, but also with
resistin levels, the product of resistin and S100A12, the
ratio of resistin to sRAGE, the ratio of S100A12 to
sRAGE, WBCs, neutrophils and CRP. Resistin and
S100A12 levels were positively correlated with the ratio of
resistin to sRAGE, the ratio of S100A12 to sRAGE, WBCs,
neutrophils and CRP.
Table 1 Characteristics of the patients with Kawasaki disease (KD) and healthy children (control group)
Characteristic Kawasaki disease Control
Acute stage P Afebrile stage P Subacute stage P
Boys/girls, number 22/18 NS 11/4
Age, months (range) 23.2 (5.1-72.0) NS 63.7 (2.6-109.0)
Days of fever (range) 6.3 (3.0-15.0) – –
Resistin, 102 ng/ml 0.38 (0.25) 0.001 0.24 (0.22) ** 0.360 0.14 (0.09) **▲ 0.405 0.19 (0.16)
S100A12, 102 ng/ml 5.33 (3.23) 0.001 4.07 (3.52) * 0.031 2.62 (2.64) **▲ 0.542 2.05 (1.81)
sRAGE, 102 pg/ml 3. 00 (1.91) 0.000 5.75 (2.83) ** 0.001 6.83 (3.07) ** 0.018 9.04 (5.28)
Resistin × S100A12, 104 2.61 (2.58) 0.000 1.20 (1.19) ** 0.122 0.24 (0.23) **▲ 0.877 0.32 (0.26)
Resistin/sRAGE, 102 2.13 (1.89) 0.000 0.39 (0.28) ** 0.708 0.21 (0.14) ** 0.884 0.26 (0.21)
S100A12/sRAGE, 103 2.61 (2.02) 0.000 0.84 (0.69) ** 0.107 0.30 (0.25) ** 0.835 0.23 (0.19)
WBCs, 104/ul 1.39 (0.49) – 1.01 (0.51) ** – 1.01 (0.51) ** – –
Neutrophils, % 55.6 (18.8) – 33.2 (17.2) ** – 33.4 (17.6) ** – –
Lymphocytes, % 32.5 (15.1) – 50.9 (16.6) ** – 54.3 (16.7) ** – –
Monocytes, % 7.81 (3.98) – 11.6 (16.6) – 8.77 (2.94) – –
Platelets, 105/ul 4.23 (1.44) – 5.68 (2.09) ** – 6.79 (1.87) **▲▲ – –
CRP, mg/l 75.1 (49.1) – 25.0 (33.8) ** – 3.25 (4.12) **▲▲ – –
ESR, mm/h 67.7 (29.7) – 78.8 (30.4) ** – 59.2 (28.3) ▲▲ – –
Results are mean (SD) unless stated otherwise. All P-values are for patients versus healthy controls. NS, not significant; sRAGE, soluble receptor for advanced
glycation end products; WBCs, white blood cells; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate. *P < 0.05, **P < 0.01 compared with acute stage; ▲P
< 0.05, ▲▲P < 0.01 compared with afebrile stage.
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Discussion
As expected, this study found that the KD patients in
the acute stage had elevated resistin and S100A12
serum levels compared with healthy children. The same
situation included the product of resistin and S100A12,
the ratio of resistin to sRAGE and the ratio of S100A12
to sRAGE. The phenomena show that various types of
inflammatory proteins are activated in KD [22,23]. How-
ever, sRAGE levels decreased in KD patients compared
with healthy children. Serum levels of resistin and
Table 2 Serum levels of resistin, S100A12 and soluble receptor for advanced glycation end products (sRAGE) in
intravenous immunoglobulin (IVIG) responding or non-responding patients with Kawasaki disease
Characteristic IVIG responders (n = 36) IVIG non-responders (n = 4) P
Boys/girls, number 21/15 1/3 0.000
Age, months 22.4 (17.2) 30.5 (12.8) 0.000
Patients with CALs, number 7 2 0.000
Resistin, 102 ng/ml Acute stage 0.35 (0.24) 0.64 (0.30) 0.032
Afebrile stage 0.21 (0.19) ** 0.48 (0.35) 0.019
Subacute stage 0.12 (0.05) **▲ 0.28 (0.19) 0.000
S100A12, 102 ng/ml Acute stage 5.05 (3.22) 7.92 (2.61) 0.044
Afebrile stage 3.99 (3.49) 4.80 (4.26) 0.668
Subacute stage 2.35 (2.26)** ▲ 4.98 (4.75) 0.047
sRAGE, 102 pg/ml Acute stage 3.07 (1.98) 2.37 (0.96) 0.493
Afebrile stage 6.00 (2.78)** 3.51 (2.64) 0.046
Subacute stage 7.19 (2.88)** 3.65 (3.27) 0.026































































































































































Figure 1 Resistin, S100A12 and soluble receptor for advanced glycation end products (sRAGE) levels at different stages of Kawasaki
disease (KD) in patients treated with intravenous immunoglobulin (IVIG). KD-I, acute stage; KD-II, afebrile stage; KD-III, subacute stage.
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S100A12 in KD patients were peaked in the acute phase
before IVIG, and returned to approximately normal
levels in the afebrile and subacute stages, respectively.
Resistin, S100A12, WBCs, neutrophils, and CRP tended
towards a similar pattern of change, which was the
opposite of the changes in expression of sRAGE, lympho-
cytes, monocytes and platelets. Resistin and S100A12
have similar significance to established inflammatory fac-
tors in KD patients. Although sRAGE could not be fully
confirmed as a protective factor, it can still be a sensitive
Table 3 Serum levels of resistin, S100A12 and soluble receptor for advanced glycation end products (sRAGE) in
Kawasaki disease (KD) with or without coronary artery lesions (CALs)





Boys/girls, number 4/5 18/13 0.000
Age, months 27.1 (20.7) 22.1 (15.6) 0.001
Resistin, 102 ng/ml Acute stage 0.46 (0.24) 0.36 (0.26) 0.268
Afebrile stage 0.31 (0.20) 0.22 (0.22) * 0.266
Subacute stage 0.15 (0.08)** ▲ 0.13 (0.08) ** 0.663
S100A12, 102 ng/ml Acute stage 5.09 (2.78) 5.40 (3.42) 0.804
Afebrile stage 4.22 (3.29) 4.02 (3.63) 0.883
Subacute stage 2.52 (3.16) 2.65 (2.53)** 0.899
sRAGE, 102 pg/ml Acute stage 2.97(1.99) 3.01 (1.92) 0.959
Afebrile stage 5.93 (3.59)* 5.70 (2.64)** 0.833
Subacute stage 7.06 (3.88)* 6.77 (2.86)** 0.802





























































































































































Figure 2 Resistin, S100A12 and soluble receptor for advanced glycation end products (sRAGE) levels at different stages of KD in
patients with and without coronary artery lesions (CALs). KD-I, acute stage; KD-II, afebrile stage; KD-III, subacute stage.
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index response to attack by pro-inflammatory agents like
S100A12 or resistin, in view of its negative correlation
with them.
Resistin is known to be secreted by adipose tissue and
by macrophages and monocytes [3,4], while S100A12 is
normally secreted by neutrophils, with low expression
on lymphocytes and monocytes [15]. Although serum
levels of S100A12 were significantly higher than the
levels of resistin in patients with KD, the change trends
were coincident for both S100A12 and resistin in the
different stages of KD. A markedly positive correlation
between serum resistin and S100A12 levels in KD has
been highlighted. Serum resistin and S100A12 levels
have shown a negative correlation with sRAGE. More-
over, resistin expression is notably correlated with neu-
trophils, but the relationship between the sources of
resistin and neutrophils still remains unclear. However,
we believe that both of them are significant in the pro-
cess of KD and it seems that resistin, S100A12, and
sRAGE are three elements of a balance with positive
and negative feedbacks, which could regulate the patho-
physiology of KD.
IVIG was not effective for all the children with KD.
Patients who did not respond had age and gender differ-
ences compared with responders. The response to IVIG
depends on children’s physiological functions and patholo-
gic state. In the acute, afebrile and subacute stages of KD,
resistin levels were higher in IVIG non-responders than in
responders, as were S100A12 levels in the acute and suba-
cute stages of KD. This suggests that the inflammatory
reaction is more severe in IVIG non-responders than in
responders. In the acute stage before IVIG treatment,
sRAGE levels were not significantly different in non-
responders compared with responders. In the afebrile and
subacute stages of KD, sRAGE levels were lower in IVIG
non-responders than in responders. This demonstrates
that the protective factor against inflammation is lower in
IVIG non-responders than in responders. It suggests that
it is possible to apply ectogenesis sRAGE to alleviate the
inflammatory reaction in IVIG non-responders.
The average serum levels of resistin, S100A12 and
sRAGE were not significantly different in the KD patients
with CALs compared to those without CALs. Serum levels
of resistin, S100A12 and sRAGE are unlikely to predict the
risk of CALs in KD patients. The results are consistent
with a recent study [24].
To our knowledge, the present study is the first simul-
taneous evaluation of resistin, S100A12 and sRAGE in
the acute, afebrile and subacute stages of KD. Also it is
the first report of higher resistin levels in IVIG non-
responders compared to IVIG responders in the acute,
afebrile and subacute stages of KD; higher S100A12 levels
in IVIG non-responders than in IVIG responders in the
acute and subacute stages of KD; and lower sRAGE levels
in IVIG non-responders than in IVIG responders in the
afebrile and subacute stages of KD.
Conclusions
In KD, sRAGE levels appear to reverse regulation with
the pro-inflammatory factor resistin and S100A12 levels.
The balance between the levels of resistin, S100A12 and
sRAGE may represent a dynamic system with the interac-
tion of positive and negative feedbacks. It suggests that
the resistin, S100A12 and sRAGE are involved in the
pathophysiology of KD.
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